
    
      Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS
      radiation therapy for up to approximately one year. The chemotherapy regimens are either:

        -  FP (5-fluorouracil [5-FU] + cisplatin) or

        -  FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).
    
  